Quick Answer
NOVAVAX INC reported Cash And Cash Equivalents At Carrying Value of $240.63 million for the year ending 2025.
- NOVAVAX INC showed a decrease of -54.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NOVAVAX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), NOVAVAX INC's Cash And Cash Equivalents At Carrying Value has grown by 793.3%.
- Historical annual values: Fiscal year 2025: $240.63 million | Fiscal year 2024: $530.23 million | Fiscal year 2023: $568.51 million | Fiscal year 2022: $1.34 billion | Fiscal year 2021: $1.52 billion | Fiscal year 2020: $553.40 million | Fiscal year 2019: $78.82 million | Fiscal year 2018: $70.15 million | Fiscal year 2017: $106.31 million | Fiscal year 2016: $144.35 million | Fiscal year 2015: $93.11 million | Fiscal year 2014: $32.34 million | Fiscal year 2013: $119.47 million | Fiscal year 2012: $17.40 million | Fiscal year 2011: $14.10 million | Fiscal year 2010: $8.06 million | Fiscal year 2009: $38.76 million | Fiscal year 2008: $26.94 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: